Five year trends in dyslipidaemia prevalence and management in Switzerland: The CoLaus study.

Détails

ID Serval
serval:BIB_41A9AD029C6F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Five year trends in dyslipidaemia prevalence and management in Switzerland: The CoLaus study.
Périodique
Nutrition, Metabolism, and Cardiovascular Diseases
Auteur(s)
Antiochos P., Marques-Vidal P., Waeber G., Vollenweider P.
ISSN
1590-3729 (Electronic)
ISSN-L
0939-4753
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
25
Numéro
11
Pages
1007-1015
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
BACKGROUND AND AIMS: Data from prospective cohorts describing dyslipidaemia prevalence and treatment trends are lacking. Using data from the prospective CoLaus study, we aimed to examine changes in serum lipid levels, dyslipidaemia prevalence and management in a population-based sample of Swiss adults.
METHODS AND RESULTS: Cardiovascular risk was assessed using PROCAM. Dyslipidaemia and low-density lipoprotein cholesterol (LDL-C) target levels were defined according to the Swiss Group for Lipids and Atherosclerosis. Complete baseline and follow up (FU) data were available for n = 4863 subjects during mean FU time of 5.6 years. Overall, 32.1% of participants were dyslipidaemic at baseline vs 46.3% at FU (p < 0.001). During this time, lipid lowering medication (LLM) rates among dyslipidaemic subjects increased from 34.0% to 39.2% (p < 0.001). In secondary prevention, LLM rates were 42.7% at baseline and 53.2% at FU (p = 0.004). In multivariate analysis, LLM use among dyslipidaemic subjects, between baseline and FU, was positively associated with personal history of CVD, older age, hypertension, higher BMI and diabetes, while negatively associated with higher educational level. Among treated subjects, LDL-C target achievement was positively associated with diabetes and negatively associated with personal history of CVD and higher BMI. Among subjects treated at baseline, LLM discontinuation was negatively associated with older age, male sex, smoking, hypertension and parental history of CVD.
CONCLUSIONS: In Switzerland, the increase over time in dyslipidaemia prevalence was not paralleled by a similar increase in LLM. In a real-life setting, dyslipidaemia management remains far from optimal, both in primary and secondary prevention.
Pubmed
Web of science
Création de la notice
08/12/2015 19:49
Dernière modification de la notice
03/03/2018 16:34
Données d'usage